Experimental drug shows promise for rare eye cancer
NCT ID NCT00244816
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tested a drug called Taxoprexin in 22 people with advanced eye melanoma that had spread to other parts of the body. The goal was to see if the drug could shrink tumors and how safe it was. Participants received weekly injections, and researchers measured tumor response, survival, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
Conditions
Explore the condition pages connected to this study.